https://www.centerforbiosimilars.com/view/biosimilar-infliximab-deemed-safe-effective-in-pediatric-patients-with-ibd
0
0
8/22/22 at 2:43pm
Organization
The Center for Biosimilars
48 words
0
Comments
Researchers found that an infliximab biosimilar was as safe and effective as the reference product (Remicade) in pediatric patients with inflammatory bowel disease. However, more studies on adalimumab biosimilars in pediatric patients are needed.
You are the first to view
Create an account
or login to join the discussion